FDA
-
-
-
-
-
-
-
BrainsWay Highlights Growing U.S. Payer Support for Nurse Practitioner-Administered Transcranial Magnetic Stimulation (TMS) Therapy
-
-
-
-
-
-
-
Landmark Data Validate BrainsWay’s SWIFT™ Deep TMS, Beginning a New Era in Depression Treatment
-
-
-
-
-
-
-
BrainsWay changes ADS-to-ordinary share ratio from 2-to-1 to 1-to-1
-
-
-
-
-
-
-
BrainsWay Announces First Coverage Policy for Accelerated Deep TMS™
-
-
-
-
-
-
-
BrainsWay Reports Third Quarter 2025 Financial Results and Operational Highlights
-
-
-
-
-
-
-
BrainsWay invests in Neurolief ahead of depression device launch
-
-
-
-
-
-
-
BrainsWay to Report Second Quarter 2025 Financial Results on August 13, 2025
-
322,245 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

